Literature DB >> 4041336

The effect of ranitidine on the disposition of lignocaine.

R A Robson, L M Wing, J O Miners, K J Lillywhite, D J Birkett.   

Abstract

The effect of pretreatment with ranitidine (150 mg twice daily for 5 days) on the disposition of lignocaine was examined in 10 healthy volunteers (five male, five female). Each subject received separate oral (250 mg) and intravenous (1.5 mg/kg) doses of lignocaine hydrochloride before and after ranitidine. Lignocaine systemic clearance was reduced by 9% (1.11 to 0.99 1 h-1 kg-1; P less than 0.01) following ranitidine pretreatment. The volume of distribution at steady-state was reduced by 15% (3.34 to 2.85 1 kg-1; P less than 0.005). Lignocaine oral clearance, elimination half-life and oral bioavailability were unchanged after ranitidine pretreatment. There was no sex difference in the effects of ranitidine pretreatment on lignocaine disposition. These results are consistent with small reductions in blood flow to the splanchnic and other vascular beds due to ranitidine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4041336      PMCID: PMC1400683          DOI: 10.1111/j.1365-2125.1985.tb05053.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Meperidine and other basic drugs: general method for their determination in plasma.

Authors:  L E Mather; G T Tucker
Journal:  J Pharm Sci       Date:  1974-02       Impact factor: 3.534

2.  The two-period cross-over clinical trial.

Authors:  M Hills; P Armitage
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

Review 3.  Drug interactions with cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

4.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

5.  Lidocaine disposition--sex differences and effects of cimetidine.

Authors:  L M Wing; J O Miners; D J Birkett; T Foenander; K Lillywhite; S Wanwimolruk
Journal:  Clin Pharmacol Ther       Date:  1984-05       Impact factor: 6.875

6.  Lack of effect of ranitidine on the disposition of lignocaine.

Authors:  J Feely; E Guy
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

7.  Increased toxicity and reduced clearance of lidocaine by cimetidine.

Authors:  J Feely; G R Wilkinson; C B McAllister; A J Wood
Journal:  Ann Intern Med       Date:  1982-05       Impact factor: 25.391

8.  Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam.

Authors:  D R Abernethy; D J Greenblatt; F N Eshelman; R I Shader
Journal:  Clin Pharmacol Ther       Date:  1984-02       Impact factor: 6.875

9.  Reduction of liver blood flow and propranolol metabolism by cimetidine.

Authors:  J Feely; G R Wilkinson; A J Wood
Journal:  N Engl J Med       Date:  1981-03-19       Impact factor: 91.245

  9 in total
  5 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 2.  Ranitidine versus cimetidine. A comparison of their potential to cause clinically important drug interactions.

Authors:  S R Smith; M J Kendall
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

Review 3.  Side effects of ranitidine.

Authors:  T Vial; C Goubier; A Bergeret; F Cabrera; J C Evreux; J Descotes
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

Review 4.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

5.  Interaction of tertatolol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity.

Authors:  W Kirch; S Milferstädt; A Halabi; I Rocher; C Efthymiopoulos; L Jung
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.